P16-INK4a and other transcription factors have been introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other nuclear proteins into primary as well as transformed cells. Recombinant human p16-INK4a-TAT expressed in E. coli is a 18 kDa protein containing 167 amino-acid residues, including the 156 residues of full-length p16-INK4a and a 13-residue C-terminal TAT peptide (GGYGRKKRRQRRR).
Batch dependent (please contact us for details)
Store at -20ºC or below. After reconstitution, keep as concentrated solution. Aliquot and avoid freeze-thaw cycles.
EPAAGSSMEP SADWLATAAA RGRVEEVRAL LEAGALPNAP NSYGRRPIQV MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL DTLVVLHRAG ARLDVRDAWG RLPVDLAEEL GHRDVARYLR AAAGGTRGSN HARIDAAEGP SDIPDGYGR KKRRQRRR
≥ 95% by SDS-PAGE and HPLC.
< 1 EU/μg
For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
cyclin dependent kinase inhibitor 2A , ARF , CDK4I , CDKN2 , CMM2 , INK4 , INK4A , MLM , MTS-1 , MTS1 , P14 , P14ARF , P16 , P16-INK4A , P16INK4 , P16INK4A , P19 , P19ARF , TP16